ClinConnect ClinConnect Logo
Search / Trial NCT06467942

Effects of Chinese Medicine and Lactobacillus in Persistent HPV Infection

Launched by PEKING UNIVERSITY PEOPLE'S HOSPITAL · Jun 15, 2024

Trial Information

Current as of June 27, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is studying the effects of Chinese medicine and a type of bacteria called Lactobacillus on women who have a persistent infection with high-risk human papillomavirus (hr-HPV). Persistent hr-HPV infections can increase the risk of developing cervical cancer, but many infections clear up on their own. The researchers want to learn how the vaginal environment and the presence of these treatments can help clear hr-HPV and prevent it from leading to more serious conditions.

Women over the age of 25 who have had the same type of hr-HPV infection for more than a year may be eligible to participate. Key requirements include having a negative or low-risk biopsy result and agreeing to use contraception during the study. Participants will receive treatments aimed at improving their vaginal environment and will be monitored over time to see how their HPV infection changes. It's important to note that women with certain higher-risk conditions or who are pregnant or breastfeeding cannot take part in this study. This trial could help improve strategies for managing persistent HPV infections and reducing the risk of cervical cancer in the future.

Gender

FEMALE

Eligibility criteria

  • Inclusion Criteria:
  • Women over 25 years of age with the same type of high-risk HPV infection lasting for more than 1 year, atypical squamous cell (ASCUS) or Low-grade squamous intraepithelial disease (LSIL) cytologically negative or undiagnosable, and pathological biopsy results negative or LSIL
  • Consent to use the device for contraception during the study period;
  • agree with medicine and follow-up management procedure.
  • Exclusion Criteria:
  • High cytological risk, including atypical squamous cells (ASC-H),HSIL and atypical glandular cell (AGC), which could not rule out high-grade squamous intraepithelial lesions;
  • pathological biopsy for HSIL and above;
  • for any drug allergies;
  • pregnancy or lactation

About Peking University People's Hospital

Peking University People's Hospital is a leading clinical research institution in China, renowned for its commitment to advancing medical knowledge and improving patient care through innovative clinical trials. Affiliated with Peking University, the hospital integrates cutting-edge research, comprehensive healthcare services, and a multidisciplinary team of experts to facilitate the development of new therapies and medical interventions. With a strong focus on patient safety and ethical standards, Peking University People's Hospital is dedicated to conducting rigorous clinical trials that contribute to the global medical community and enhance the quality of life for patients.

Locations

Beijing, Beijing, China

Patients applied

0 patients applied

Trial Officials

Mingzhu Li

Principal Investigator

Peking University People's Hosptial

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported